| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 07/25/2023 | 10.55% | Guggenheim | $252 → $273 | Maintains | Buy |
| 05/08/2023 | 2.05% | Guggenheim | → $252 | Upgrades | Neutral → Buy |
| 02/15/2023 | -5.65% | Baird | $226 → $233 | Maintains | Neutral |
| 10/27/2022 | — | UBS | Upgrades | Sell → Neutral | |
| 10/26/2022 | -12.12% | Baird | $200 → $217 | Maintains | Neutral |
| 09/07/2022 | -42.5% | UBS | → $142 | Initiates Coverage On | → Sell |
| 05/24/2022 | — | Guggenheim | Initiates Coverage On | → Neutral | |
| 07/20/2021 | -16.98% | Credit Suisse | $200 → $205 | Maintains | Outperform |
| 03/17/2021 | -26.7% | Credit Suisse | $178 → $181 | Maintains | Outperform |
| 02/17/2021 | -27.11% | Truist Securities | $135 → $180 | Maintains | Buy |
| 02/16/2021 | -27.92% | Credit Suisse | $155 → $178 | Maintains | Outperform |
| 10/02/2020 | -45.33% | Truist Securities | $124 → $135 | Upgrades | Hold → Buy |
| 07/28/2020 | -53.83% | Credit Suisse | $92 → $114 | Maintains | Outperform |
| 06/08/2020 | -66.39% | Baird | → $83 | Upgrades | Underperform → Neutral |
| 04/30/2020 | -65.58% | SunTrust Robinson Humphrey | $54 → $85 | Upgrades | Sell → Hold |
| 04/29/2020 | -62.74% | Credit Suisse | $105 → $92 | Maintains | Outperform |
| 04/20/2020 | -68.82% | Baird | → $77 | Downgrades | Neutral → Underperform |
| 04/06/2020 | -78.13% | SunTrust Robinson Humphrey | $46 → $54 | Maintains | Sell |
| 03/23/2020 | -69.63% | Jefferies | $93 → $75 | Maintains | Hold |
| 03/17/2020 | -81.37% | SunTrust Robinson Humphrey | $100 → $46 | Downgrades | Hold → Sell |
| 02/25/2020 | -59.91% | Credit Suisse | $91 → $99 | Maintains | Outperform |
| 01/27/2020 | -64.77% | SunTrust Robinson Humphrey | $85 → $87 | Downgrades | Buy → Hold |
| 04/30/2019 | -74.89% | Baird | $57 → $62 | Maintains | Neutral |
| 10/31/2018 | — | SunTrust Robinson Humphrey | Upgrades | Hold → Buy | |
| 08/02/2018 | -75.3% | Credit Suisse | $49 → $61 | Maintains | Outperform |
| 07/31/2018 | -80.16% | Credit Suisse | $42 → $49 | Maintains | Outperform |
| 07/31/2018 | — | William Blair | Upgrades | Market Perform → Outperform |
What is the target price for Medpace Hldgs (MEDP)?
The latest price target for Medpace Hldgs (NASDAQ: MEDP) was reported by Guggenheim on July 25, 2023. The analyst firm set a price target for $273.00 expecting MEDP to rise to within 12 months (a possible 10.55% upside). 6 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Medpace Hldgs (MEDP)?
The latest analyst rating for Medpace Hldgs (NASDAQ: MEDP) was provided by Guggenheim, and Medpace Hldgs maintained their buy rating.
When is the next analyst rating going to be posted or updated for Medpace Hldgs (MEDP)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Medpace Hldgs, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Medpace Hldgs was filed on July 25, 2023 so you should expect the next rating to be made available sometime around July 25, 2024.
Is the Analyst Rating Medpace Hldgs (MEDP) correct?
While ratings are subjective and will change, the latest Medpace Hldgs (MEDP) rating was a maintained with a price target of $252.00 to $273.00. The current price Medpace Hldgs (MEDP) is trading at is $246.94, which is out of the analyst's predicted range.